Cite

HARVARD Citation

    Huynh, L. et al. (2017). Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR. Journal of medical economics. pp. 945-951. [Online]. 
  
Back to record